Not to inj via IV or IM. Not to be used for acute asthma exacerbations, acute bronchospasm or status asthmaticus. Consider discontinuation if patients do not respond to recommended anti-helminth treatment. Anaphylaxis & anaphylactoid reactions; serum sickness & serum sickness-like reactions. Known history of anaphylaxis. Atopic dermatitis, allergic rhinitis or food allergy. Patients at high risk of helminth infection; w/ hyper-IgE syndrome or allergic bronchopulmonary aspergillosis; autoimmune diseases, immune complex-mediated conditions. Latex-sensitive individuals. Abrupt discontinuation of systemic or inhaled corticosteroids after initiation of therapy in allergic asthma or nasal polyps. Measure baseline IgE & body wt before starting treatment. Pre-existing renal or hepatic impairment. Increased risk of pre-eclampsia in women w/ poorly or moderately controlled asthma & premature, low birth wt, & small for gestational age in neonate. Closely monitor asthma level in pregnant women. Pregnancy & lactation. Not recommended in childn <6 yr w/ allergic asthma; <12 yr w/ CSU; <18 yr w/ nasal polyps. Elderly ≥65 yr.
Sign Out
